– Tetra Pharm Technologies completes preclinical testing of TPT0301 in preparation for first human clinical trials
COPENHAGEN, Denmark, Sept. 6, 2023 /PRNewswire/ — Following convincing results from a recent in-vitro study, Danish biotech company Tetra Pharm Technologies today announces successful results from the in-vivo study of its candidate compound, TPT0301. .
The In-Vivo study focuses on establishing the pharmacokinetic profile of TPT0301 in rats fasted for 24 hours after gastrointestinal (GI) administration. The candidate compound was formulated using Tetra Pharm Technologies’ proprietary drug delivery technology and compared to a simplistic formulation principle commonly used for cannabinoids.
“In vivo testing establishes essential pharmacokinetic information, demonstrating a significantly faster onset of absorption and high exposure of TPT0301 after gastrointestinal administration. The combined preclinical package, i.e., including previously announced in vitro results confirming a high permeability through the mucosa in the mouth, is unique in that it establishes the effectiveness of our drug delivery technology in two types of oral administration: orally to the gastrointestinal tract and sublingually, i.e. under the tongue In the case of the latter, the fraction of dose, inevitably lost in the gastrointestinal tract, will be largely absorbed.Therefore, preclinical data confirm the suitability of TPT0301 for sublingual administration and, at the same time, provide us with the option to consider conventional oral administration,” said Dr. Morten Allesø, Chief Scientific Officer of Tetra Pharm Technologies.
The target of TPT0301 is the endocannabinoid system (ECS), which is a generalized neuromodulatory system that regulates and controls various physiological processes to maintain balance and homeostasis within the human body, such as learning and memory, emotional processing, sleep , temperature and pain control, inflammatory and immune responses, and appetite.
“The demonstrated strong preclinical performance of TPT0301 increases our confidence in the upcoming first human trials. Achieving a robust blood plasma profile is a key factor in finding successful doses,” added Dr. Morten Allesø.
Tetra Pharm Technologies is currently planning for the first human trials of TPT0301 to begin in Q4 2023.
“We are very excited about the results of the preclinical studies of TPT0301 and look forward to starting the first phase of clinical studies. Research and development is our top priority and we will continue to invest in building our pipeline of new drug candidates targeting the endocannabinoid system. (ECS) and related disease indications,” said Martin Rose, CEO of Tetra Pharm Technologies.
About Tetra Pharm Technologies
Tetra Pharm Technologies is a Danish biopharmaceutical company established in 2018 with the vision to be a leader in research and development of drugs for the treatment of diseases related to the endocannabinoid system. For more information visit www.tetrapharm.eu
For more information, visit: Martin Caspersencap@tetrapharm.eu 45 61224241
Photo – https://mma.prnewswire.com/media/2197602…Logo – https://mma.prnewswire.com/media/1988863…
View original content: https://www.prnewswire.com/news-releases/tetra-pharm-technologies-concluye-las-pruebas-preclinicas-de-tpt0301-301913666.html
